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 Abstract
Human cytochrome P450 1A1 is one of the most important enzymes participating in human carcinogenesis 
because it metabolites several procarcinogens to active carcinogenic metabolites. Additionally, enzymes of CYP450 
family play an important role in estrogenes catabolization (17-β-estradiol and estron) to intermediate products (2-, 
4-hydroxyestradiol and 2-, 4-hydroxyestrone) including CYP1A1 that catalyses hydroxylation to 2-hydroxyestrogens 
in the endometrium. Derivates of these compounds (4-hydroxyestrogens) are carcinogenic and could induce DNA 
damage leading to tumour transformation. The presence of CYP1A1 enzyme in genital tract tissues could induce 
chemical carcinogenesis initiating cancer development. 
Recent studies also confirmed the role of CYP1A1 in the development of ovarian and endometrial cancer in humans. 
The presence of mutated CYP1A1 polymorphic variants influencing the CYP1A1 activity could be responsible for 
different interindividual susceptibility to genital cancers in women.
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Introduction
Ovarian	 and	 endometrial	 cancers	 are	 serious	 medical	 and	
social	 problems	 of	 women	 with	 not	 fully	 explained	 etiology.	
Many	 risk	 factors	 for	 ovarian	 and	 endometrial	 cancers	
were	 already	 recognised	 (childless,	 obesity,	 consumption	 of	
animal	 fat,	 exposition	 to	 asbestos	 and	 talc	 for	 ovarian	 cancer;	
hyperestrogenism,	late	menopause,	obesity,	diabetes	mellitus	and	
hypertension	 for	 endometrial	 cancer)	 [1,2].	Besides	 the	 above-
mentioned,	in	recent	years	the	genetic	background	was	shown	to	
be	involved	in	the	etiology	of	these	cancers	[3].	The	genes	such	as	
protooncogenes	(AKT2, Ki-Ras),	tumor	suppressor	genes	(TP53, 
BRCA1, BRCA2)	and	mismatch	repair	genes	(MSH2, MLH1) were 
indicated	 to	 be	 involved	 in	 the	 pathogenesis	 of	 ovarian	 cancer	
[4,5].	The	question	remains	what	is	the	role	of	polymorphic	genes	
that	modulate	individual	susceptibility	to	cancerogenesis.
The	 activity	 of	 carcinogen	 metabolizing-enzymes	 in	 the	
etiology	of	urogenital	cancers	is	still	unclear	but	preliminary	reports	
indicate	 modulating	 role	 of	 themin	 urogenital	 carcinogenesis.	
Recently	 however,	 high	 levels	 of	 transcripts	 of	 dioxin-induced	
gene	 (CYP1A1)	 were	 found	 in	 endometriotic	 tissues	 [6].	 The	
presence	of	CYP1A1	enzyme	in	genital	tract	tissues	could	induce	
chemical	 carcinogenesis	 initiating	 cancer	 development.	 It	 was	
assumed	 that	 presence	 of	 mutated	 CYP1A1	 variants	 could	 be	
responsible	for	different	 interindividual	susceptibility	to	genital	
tract	cancers.
Number	of	studies	had	proven	that	there	is	an	independent	
effect	of	polymorphic	variants	of	CYP450	genes	on	the	activity	and	
the	level	of	endogenous	steroid	hormones	and	the	risk	of	cancer.	
Allelic	variants	of	cytochrome	P450,	among	them	the	CYP1A1 
gene,	are	associated	with	a	high	risk	of	hormone-dependent	cancers	
[1,2,7].	 Moreover,	 the	 metabolism	 of	 numerous	 carcinogens	
by	 the	cytochrome	P450	enzymes	 including	CYP1A1	can	also	
lead	 to	different	 types	of	cancer.	Because	of	 the	 importance	of	
investigations	 connected	 with	 ovarian	 and	 endometrial	 cancer	
etiology	the	goal	of	this	manuscript	is	to	briefly	summarize	the	
significance	 of	CYP1A1	 genetic	 polymorphism	 in	 ovarian	 and	
endometrial	cancers	[8,9].
CYP1A1 – etiological considerations in urogenital cancers
The	 cytochrome	 P450	 (CYP)	 superfamily	 is	 a	 large	 and	
diverse	group	of	enzymes	(hemoproteins)	that	participate	in	phase	
I	metabolism	 reactions.	These	monooxygenases	 are	 capable	 of	
catalyzing	metabolism	of	various	xenobiotic	chemicals	including	
drugs,	procarcinogens	as	well	as	endobiotic	chemicals	including	
fatty	 acids,	 steroids,	 eicosanoids,	 retinoids	 and	 prostaglandins	
[10-12].	Human	cytochrome	P450	is	a	gene	family	consisting	of	
57	protein-coding	genes	and 58	pseudogenes	classified	 into	18	
families	and	43	subfamilies based	upon	similarities	in	amino	acid	
sequences	 [13,14].	The	CYP	enzymes	are	present	 in	almost	all	
human	tissues,	but	 they	are	most	active	 in	 liver	and	suprarenal	
glands.	 In	 humans,	 the	 complex	 of	 cytochrome	 P450	 contains	
more	 than	15	different	 enzymes	which	all	play	a	 role	 in	drugs	
and	 procarcinogens	 metabolism	 as	 well	 as	 steroid	 hormones	
biochemical	transformation.	
The	cytochrome	P450	family	was	particularly	well	studied	
with	regard	to	genetic	polymorphisms	and	activity	of	enzymes.	
In	recent	years	also	its	connection	with	development	of	different	
disorders	was	widely	 discussed.	The	 best	 studied	 cytochromes	
are	CYP2D6,	CYP2C9,	CYP2C19	and	CYP1A1	[12,15].
Human	cytochrome	P450	1A1	(named	CYP1A1,	see	http://
www.imm.ki.se/	 CYPalleles/cyp1A1.htm)	 is	 one	 of	 the	 most	
important	enzymes	in	human	carcinogenesis	because	it	metabolites	
several	 procarcinogens	 to	 active	 carcinogenic	 metabolites.	
CYP1A1	oxygenates	polycyclic	aromatic	hydrocarbons	(PAHs),	
including	many	 procarcinogenes	 (e.g.	 benzo[a]pyrene)	 to	 their	
final	water-soluble	derivatives	with	carcinogenic	activity.	Dioxins	
are	strong	CYP1A1	inducers,	and	the	most	common	of	them	is	
2,3,7,8-tetrachlorodibenzo-p-dioxin	(TCDD).	Dioxins	bind	to	an	
intracellular	aryl	hydrocarbon	receptor	(AhR)	that	induces	mRNA	
transcription	followed	by	activation	of	xenobiotic-metabolizing	
enzymes	known	as		CYP1A1,	CYP1A2	and	CYP1B1	[16,17].
Cytochrome	 CYP1A1	 is	 involved	 in	 the	 I	 phase	 of	
biotransformation,	 and	 substrates	 for	CYP1A1	 enzyme	 are	 not	
only	 PAHs	 and	 dioxins	 but	 also	 drugs,	 hormones	 and	 other	
chemical	compounds	(Table	I)	[18].	
 Streszczenie  
Ludzki cytochrom CYP4501A1 jest jednym z najważniejszych enzymów uczestniczących w procesie kancerogene-
zy, ponieważ metabolizuje wiele pro-kancerogenów do ich aktywnych kancerogennych metabolitów. 
Dodatkowo, enzymy z rodziny CYP450 odgrywają ważną rolę w katabolizmie estrogenów (17-β-estradiol i estron) 
do produktów pośrednich (2-, 4-hydroksyestradiol oraz 2-, 4-hydroksyestron) uwzględniając CYP1A1, który kata-
lizuje hydroksylację do 2-hydroksyestrogenu w endometrium. Pochodne tych związków (4-hydroksyestrogeny) są 
kancerogenne i mogą indukować uszkodzenia DNA prowadząc do transformacji nowotworowej komórki. Obec-
ność enzymu CYP1A1 w tkankach narządów płciowych może indukować chemiczną kancerogenezę inicjując roz-
wój nowotworu. 
Najnowsze badania potwierdziły rolę CYP1A1 w rozwoju raka jajnika i endometrium. Obecność zmutowanych 
wariantów polimorficznych genu CYP1A1 wpływających na aktywność CYP1A1 może być związana ze zróżnico-
waniem osobniczym w podatności na nowotwory narządów płciowych u kobiet.
 Słowa kluczowe: cytochrom P450 / CYP1A1 / polimorfizm / 
      / rak jajnika / rak endometrium / prokancerogeny /   
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The	subfamily	of	CYP1A	(including	CYP1A1	and	CYP1A2)	
contains	conservative	enzymes	with	80%	of	homology	between	
different	 species	 such	 as	 mice,	 rats,	 monkeys,	 and	 humans	
[20].	 CYP1A1	 is	 widely	 expressed	 first	 of	 all	 in	 lung,	 breast,	
lymphocytes	and	in	placenta	during	pregnancy.	This	enzyme	is	
also	 inducible	 in	 endothelial	 and	 epithelium	 cells	 of	 skin	 and	
intestinal	cells,	such	as	in	embryonic	cells.	In	recent	years,	several	
authors	paid	the	attention	to	possible	significance	of	expression	
alteration	 of	CYP1A1	 in	women	with	 ovarian	 and	 endometrial	
cancers.
In	 addition,	 it	 was	 indicated	 that	 CYP	 enzymes	 play	 an	
important	role	in	catabolization	of	estrogenes	(17-β-estradiol	and	
estron)	to	intermediate	products	(2-	or	4-hydroxyestradiol	and	2-	
or	4-hydroxyestrone)	[21,	22].	CYP1A1	catalyses	2-hydroxylation	
to	 2-hydroxyestrogens	 in	 the	 endometrium.	 Derives	 of	
2-hydroxyestrogens	 (4-hydroxyestrogens)	 are	 carcinogenic	 and	
could	induce	DNA	damage	[23].	Recent	approaches	demonstrate	
that	 selective	 estrogen	 receptor	 modulators	 (SERMs)	 like	
tamoxifen,	raloxifene	probably	increase	the	risk	of	endometrial	
cancer	by	enhancing	the	local	estrogen	biosynthesis	and	directing	
estrogen	 metabolism	 towards	 the	 formation	 of	 genotoxic	 and	
hormonally	 active	 estrogen	 metabolites	 with	 association	 of	
estrogen	metabolizing	enzymes	 	 -	CYP1A1,	CYP1B1,	COMT,	
NQO1,	and	SF-1	[24].
CYP1A1 and its genetic polymorphism
The	human	CYP1A1	gene	coding	CYP1A1	protein	is	located	
on	chromosome	15	(15q24.1,	7	exons,	512	residues).	The	CYP1A1 
has	been	cloned	and	amino-acid	sequence	of	CYP1A1	enzyme	
has	 been	 fully	 characterized.	 Several	CYP1A1	 polymorphisms	
have	been	previously	described	in	humans.	
Two	different	nomenclature	systems	for	the	CYP1A1 alleles 
that	could	lead	to	the	potential	confusion	have	been	developed.	
The	authors	of	both	nomenclature	systems	have	agreed	 in	July	
2000	that	the	nomenclature	system	given	on	the	homepage	[http://
www.cypalleles.ki.se/cyp1a1.htm]	 should	 be	 the	 recommended	
one	[25].	(Table	II).
In	the	human	for	CYP1A1	gene,	four	base	substitutions	were	
recognised.	 Mutation	 m2	 (CYP1A1*2C)	 exchanges	 isoleucine	
462	to	valine,	the	neighbouring	m4	exchanges	threonine	461	to	
asparagine	[26].	Mutations	m1	(CYP1A1*2A)	and	m3	(CYP1A1*3) 
are	located	in	the	3’-flanking	region,	while	m3	has	been	detected	
only	 in	Africans	 [27].	Functional	 consequences	of	m1	 and	m2, 
compared	to	wild-type	(CYP1A1*1),	have	been	presented	as	an	
increase	 in	catalytic	activity	and	a	higher	extent	of	 inducibility	
[28].	
An	attractive	 interest	of	CYP1A1	molecular	alterations	has	
been	strongly	linked	to	differences	in	the	distribution	of	genetic	
polymorphisms	 in	different	ethnic	populations	worldwide	 [29].	
For	 instance,	 Inoue	 and	 co-workers	 have	 studied	 39	 Japanese	
and	45	Caucasian	samples	assessing	the	prevalence	of	CYP1A1 
and	 CYP1B1	 polymorphisms.	 They	 reported	 that	 distributions	
of	 the	CYP1A1*2A	 and	CYP1A1*2C	 alleles	 were	 found	more	
common	in	the	Japanese	population	compared	to	the	Caucasians.	
Interestingly,	CYP1A1*4	 polymorphism	 has	 been	 not	 detected	
in	the	Japanese	group.	In	conclusion	they	suggested	that	ethnic-
related	differences	 in	 the	occurrence	of	genetic	polymorphisms	
may	determine	the	different	susceptibilities	in	individuals	towards	
environmental	 procarcinogens	 [30].	 In	 Japan,	 the	 frequency	 of	
CYP1A1*2A		and	CYP1A1*2C	alleles	was	higher	in	the	subjects	
with	 lung	 cancer	 [31].	 This	 observation	 was	 not	 confirmed	 in	
Europe,	 however	 the	 frequency	 of	 CYP1A1 point mutations 
is	 different	 in	 the	 various	 populations	 from	 small	 number	 of	
Caucasians	to	higher	frequency	in	the	Far	East	[28,32,33].
	 In	 recent	 years,	 many	 investigation	 of	 CYP1A1 
polymorphism	 in	 various	 ethnic	 groups	 were	 performed.	 The	
different	mutations	frequency	of	CYP1A1	 in	 the	different	races	
was	shown.	 In	Caucasians,	 the	highest	 frequency	of	*2A allele 
was	found	 in	 the	USA	(13.4%)	and	Norway	(11.5%),	and	 they	
observed	no	presence	of	*4	allele	[33,34].	The	higher	frequency	
of	*4	 allele	was	 shown	 in	Turkish	 healthy	 population	 –	 5.7%.	
In	 this	 group,	 alleles	 of	 *2A	 and	 *2C	 occurred	 with	 18.1%	
and	 8.9%	 frequency,	 respectively	 [35].	 Contrarily,	 the	 highest	
frequency	of	*2A		and	*2C	alleles	was	found	in	Japan	[36,	37].	
Table I. CYP1A1 substrates [19]. 
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The	CYP1A1*3	allele	was	only	represented	in	the	Afro-American	
population	in	the	USA	and	not	detected	in	any	other	population	
[29,38].	These	investigations	showed	that	in	healthy	populations	
the	polymorphism	of	CYP1A1	has	a	great	population	variability.	
Thus	the	obtained	results	of	mutated	alleles	of	CYP1A1	have	to	
be	compared	with	the	same	healthy	population. 
In	 Polish	 population	 (Wielkopolska	 region)	 alleles	 of	
*2A, *2C, *4	 occurred	with	 6.6%,	 2.2%	 and	 2.0%	 frequency,	
respectively.	The	CYP1A1*3	was	not	detected	[39].	Butykiewicz	
et	al.	and	Motykiewicz	et	al.	investigated	the	healthy	population	
in	Silesian	region	(South	West	part	of	Poland)	mutation	CYP1A1 
and	 found	 2-fold	 higher	 frequency	 of	 *2C	 allele	 than	 in	 the	
general	population	[40,41].
CYP1A1 polymorphisms and ovarian cancer
Recently,	 the	 hypothesis	 that	 CYP1A1	 polymorphism	 is	
a	 susceptibility	 carcinogenic	 factor	 in	 genital	 tract	 tissue,	 was	
discussed	for	ovarian	cancer.	Recent	studies	have	also	shown	a	
correlation	between	these	polymorphisms	and	a	different	response	
to	the	same	therapy	and	the	related	toxicity	among	ovarian	cancer	
patients	[42].	Aktas	et	al.	have	shown	that	presence	of	*2C allele 
predicts	 higher	 occurrence	 of	 ovarian	 cancer	 [43].	 Goodman	
et	 al.	 presented	 a	 case-control	 study,	 performed	 between	 1993	
and	 1994	 in	Hawaii,	 of	 ovarian	 cancer	 and	 polymorphisms	 in	
genes	 involved	 in	 catecholestrogen	 formation	 and	metabolism.	
The	study	involved	129	epithelial	ovarian	cancer	cases	and	144	
controls.	 They	 found	 no	 association	 between	 the	CYP1A1*2A 
(MspI)	polymorphism	and	ovarian	cancer,	however	they	revealed	
a	positive	statistical	interaction	between	tobacco	smoking	and	the	
CYP1A1*2A	polymorphism	on	the	risk	of	ovarian	cancer	[44].
In	 the	 study	 made	 by	 Delort	 et	 al.	 patients	 with	 ovarian	
cancer	were	genotyped	for	eleven	polymorphisms	in	seven	genes	
(including	 CYP1A1	 polymorphism)	 involved	 in	 estrogen	 and	
xenobiotic	metabolism.	The	studied	mutations	increased	ovarian	
cancer	risk,	but	the	results	were	not	statistically	significant	[45].
Terry	 et	 al.	 examined	 the	 association	 between	 two	
polymorphic	variants	of	CYP1A1*2A/C	 (MspI	 and	 Ile/Val)	 and	
ovarian	cancer	risk.	The	study	involved	445	ovarian	cancer	cases	
and	 472	 general	 population	 controls.	 There	 was	 no	 increased	
risk	for	ovarian	cancer	associated	with	either	the	MspI or Ile/Val 
polymorphism.	 Elevated	 risk	 for	 ovarian	 cancer	 was	 found	 in	
patients	with	Ile/Val	genotype	who	consumed	more	than	median	
levels	of	caffeine	[46].
Heubner	 et	 al.	 investigated	 the	 impact	 of	 the	CYP1A1*2C 
(Ile462Val)	 polymorphism	 on	 the	 ovarian	 cancer	 risk	 and	 the	
disease	 progression.	 They	 observed	 a	 significant	 association	
between	 the	 presence	 of	 the	462Ile	 allele	with	 ovarian	 cancer.	
Besides	 that	 fact	 the	 study	 revealed	 statistically	 significant	
association	 between	 the	462Val	 allele	 and	 platinum	 resistance,	
which	 was	 defined	 as	 a	 time	 interval	 <6	 months	 to	 disease	
progression	 after	 administration	 of	 a	 platinum-based	 primary	
chemotherapy	[47].
Some	 opposite	 results	 to	 the	 above	 mentioned	 data	 were	
presented	 by	Holt	 et	 al.	They	 carried	 out	 a	 case	 control	 study	
of	310	epithelial	ovarian	cancer	cases	and	585	controls.	Patients	
were	 genotyped	 among	 others	 for	 CYP1A1*2A, *2C, *3	 and	
*4	 polymorphisms.	 No	 association	 of	 ovarian	 cancer	 risk	was	
observed	with	any	of	these	polymorphisms	[7].
Moreover,	there	are	only	few	researches	concerning	the	role	
of	CYP1A1	alleles	in	female	genital	cancers	in	Polish	population.	
One	of	these	performed	by	Seremak-Mrozikiewicz	et	al.	showed	
higher	frequency	of	heterozygotic	genotype	containing	mutation	
m4	(CYP1A1*1/*4)	in	ovarian	cancer	group	(5.1%	versus	1.9%	
controls).	 The	 Authors	 concluded	 that	 the	 higher	 frequency	
of	 mutated	 CYP1A1*4	 allele	 connected	 with	 lower	 frequency	
of	 CYP1A1*2A	 and	 CYP1A1*2B	 in	 endometrial	 and	 ovarian	
cancer	groups	indicates	that	differences	in	the	metabolic	activity	
of	CYP1A1	could	play	a	significant	role	in	the	pathogenesis	of	
genital	tract	cancers	[8].
Table II. CYP1A1 alleles nomenclature and functional consequences [http://www.cypalleles.ki.se/cyp1a1.htm]. 
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Table III. Studies assessing the CYP1A1 genetic polymorphisms in women with ovarian cancer. 
Table IV. Studies assessing the CYP1A1 genetic polymorphisms in women with endometrial cancer. 
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In	 the	 study	 performed	 by	Mikhailova	 et	 al.,	 the	Authors	
assessed	frequency	of	allelic	variants	of	CYP1A1, CYP1A2, CYP19 
and	SULT1A1	genes	and	their	association	with	the	risk	of	ovarian	
and	endometrial	cancers.	This	investigation	involved	Caucasian	
population	 from	 Novosibirsk	 region	 (Russia).	 The	 Authors	
studied	 the	 following	 polymorphisms:	 CYP1A1*2A	 (T264C),	
CYP1A2*1F	 (C734A),	 CYP19	 (Arg264Cys)	 and	 SULT1A*2 
(Arg213His).	 In	 this	 study	 there	was	no	positive	correlation	of	
CYP1A1	polymorphism	and	elevated	risk	of	cancers	[48].
The	findings	of	these	studies	about	CYP1A1	polymorphism	
in	women	with	ovarian	cancer	were	listed	in	Table	III.	Based	on	
the	results	presented	in	this	table,	we	concluded	that	CYP1A1*4 
carriers	 were	 at	 higher	 risk	 of	 ovarian	 cancer.	 A	 moderate	
increase	 in	 risk	 of	 this	 cancer	 was	 noted	 among	 carriers	 of	
CYP1A1*2A/C.
CYP1A1 polymorphisms and endometrial cancer
There	is	limited	number	of	studies	worldwide	assessing	the	
frequency	distribution	of	genetic	polymorphisms	in	women	with	
endometrial	cancer,	but	some	genetic	researches	were	connected	
with	this	problem	[1,8,49,50].	In	the	first	report	of	Esteller	and	
co-investigators,	 DNA	 isolated	 from	 80	 unrelated	 Caucasian	
women	 diagnosed	 with	 endometrial	 cancer	 was	 analyzed	
to	 examine	 two	 polymorphisms	 in	 the	 CYP1A1 as potential 
molecular	markers	 of	 uterine	 tumour.	A	 statistically	 significant	
association	was	 reported	between	 endometrial	 cancer	 and	both	
polymorphism	studied	(p=0.02;	the	OR	and	CI	were	3.67	for	both	
polymorphisms,	 respectively).	 No	 significant	 differences	 were	
found	in	the	distribution	of	gene	polymorphisms	and	histological	
type	of	the	neoplasms	[50].
In	 Japan,	 Sugawara	 et	 al. have	 studied	 two	 CYP1A1 
polymorphisms	 (MspI	 at	 non-coding	 3’-flanking	 region	 and	
another	 at	 exon	 7)	 in	 159	 female	 genital	 tract	 malignancies,	
including	 thirty-eight	 endometrial	 cancer	 (EC)	 women.	 The	
OR	 (1.7)	 of	 Ile/Val	 (CYP1A1*2C)	 polymorphism	 was	 higher	
in	 endometrial	 cancer	 group	 than	 those	 in	 the	 cervical	 cancer	
(OR=1.18)	and	ovarian	cancer	(OR=1.16)	groups.	Moreover,	the	
Val/Val	 genotype	was	 reported	more	 frequently	 in	 endometrial	
cancer	group	compared	 to	 the	control	subjects.	However,	 there	
was	no	significant	association	between	gene	polymorphisms	and	
pathological	features	of	gynaecological	malignancies	[1].	
Sergentanis	 et	 al.	 performed	 a	 meta-analysis	 in	 order	 to	
examine	 the	 influence	 of	 three	 polymorphisms	of	CYP1A1*2A 
(MspI), *2C	 (Ile462Val)	 and	 *4	 (Thr461Asp)	 on	 endometrial	
cancer	 risk	 in	Caucasian	 population.	The	Authors	 observed	 no	
association	 between	 these	 three	 analysed	 polymorphisms	 and	
endometrial	cancer	risk	[51].
In	 the	 study	 by	 McGrath	 et	 al.,	 three	 polymorphisms	 of	
CYP1A1*2A	(MspI), *4	(Thr461Asp)	and	*2C	(Ile462Val) were 
evaluated	 as	 potential	 risk	 factors	 of	 endometrial	 cancer	 and	
their	modification	by	cigarette	smoking	among	456	women	with	
uterine	neoplasms	and	1134	matched	controls.	They	observed	no	
statistically	significant	associations	between	these	polymorphisms	
and	endometrial	cancer	risk	or	any	significant	effect	modification	
by	cigarette-smoking	[52].
In	our	study	we	analysed	71	Polish	women	with	endometrial	
cancer	in	order	to	elucidate	the	possible	role	of	CYP1A1 alleles 
in	 the	 pathogenesis	 of	 this	 malignancy.	 We	 have	 noticed	 the	
overrepresentation	of	CYP1A1*4	allele	in	both,	endometrial	and	
ovarian	 cancer	 groups	 if	 compared	 to	 the	 controls	 (CYP1A1*4 
2.8%	vs.	0.9%	in	endometrial	cancer	group	and	CYP1A1*4	2.5%	
vs.	0,9%	in	ovarian	cancer	group,	p=ns,	OR=3.0	in	endometrial	
cancer	group	and	OR=2.9	in	ovarian	cancer	group).	The	presence	
of	CYP1A1*1/*4	 genotype	was	 also	 higher	 in	 the	 endometrial	
cancer	group	compared	to	the	controls	(5.6%	vs.	1.9%).	In	our	
controls,	we	have	found	frequencies	of	CYP1A1 alleles similar 
to	other	Caucasians	 [8].	Our	 results	were	 similar	 to	 the	 results	
obtained	in	other	investigations.	It	is	possible	that	the	presence	of	
*4	allele	in	subjects	with	these	cancers	could	play	an	important	
role	 in	 the	 pathogenesis	 of	 their	 cancers.	The	 summary	 of	 the	
above-mentioned	researches	was	listed	in	Table	IV.
Gulyaeva	et	al.	studied	the	frequency	of	CYP1A1, CYP1A2, 
CYP1B1, CYP19	 and	 SULT1A1	 allelic	 variants	 in	 a	 female	
population	of	the	Novosibirsk	district	and	their	association	with	
the	elevated	risk	of	breast,	ovarian,	and	endometrial	cancers.	The	
Authors	revealed	significant	differences	(OR=2.34,	p=0.0002)	in	
the	allele	distributions	 for	CYP1A1*2A	polymorphism	between	
patients	 with	 breast	 cancer	 (118	 patients)	 and	 controls	 (180	
women).	 There	 were	 no	 statistically	 significant	 differences	 in	
genotype	 and	 allele	 distributions	 for	 CYP1A1	 polymorphisms	
in	 patients	 with	 ovarian	 cancer	 (96	 patients)	 and	 endometrial	
cancer	 (154	 patients).	 Moreover,	 differences	 in	 the	 allele	 and	
genotype	distributions	for	CYP1A2*1F	polymorphism	in	patients	
with	breast	cancer	and	ovarian	cancer	 (OR=0.26,	p=0.0000005	
and	 OR=0.34,	 p=0.00000002)	 were	 observed.	 There	 were	 no	
significant	differences	for	this	polymorphism	in	women	with	EC	
[53].
In	study	performed	by	Hirata	et	al.	150	cases	of	endometrial	
cancer	 and	 165	 healthy	 controls	were	 assessed	 to	 evaluate	 the	
genotype	 frequencies	 of	 13	 different	 polymorphisms	 of	 the	
CYP1A1 (*2A, *2C, *3, *4), CYP1A2*1F, CYP1B1	codon	432,	
COMT	codon	158,	CYP17, SULT1A1	(Arg213His,	14A/G,	85C/T	
in	the	3’	flanking	region),	SULT1E1-64G>A	promoter	region,	and	
SHBG	genes.	The	decreased	frequency	of	TC+CC	genotypes	of	
the	 CYP1A1*2A	 polymorphism	 was	 observed	 in	 EC	 patients	
in	 comparison	 to	 controls	 (OR=0.42).	 The	 T-A	 haplotype	 of	
CYP1A1*2A	and	CYP1A1*2C	polymorphisms	were	increased	in	
the	study	group	[23].
McGrath	et	al.	examined	the	associations	between	CYP1A1 
polymorphisms	and	endometrial	cancer	risk	and	the	modification	
of	these	associations	by	cigarette	smoking.	The	Authors	studied	
*2B	(MspI), *4	and	*2C	(Ile462Val) polymorphism	among	456	
women	 with	 endometrial	 cancer	 and	 1134	 healthy	 controls.	
There	were	no	statistically	significant	associations	between	these	
polymorphisms	and	endometrial	cancer	risk	or	significant	effect	
modification	by	cigarette	smoking	[52].
A	case-control	study	involving	502	patients	with	endometrial	
cancer	and	1326	healthy	controls	was	undertaken	by	Rebbeck	et	
al.	The	Authors	genotyped	the	following	genes:	COMT, CYP1A1, 
CYP1A2, CYP1B1, CYP3A4, PGR, SULT1A1, SULT1E1	 and	
UGT1A1.	The	results	 revealed	 the	association	between	the	risk	
of	endometrial	cancer	and	CYP1A1*2C	(OR=1.68),	SULT1A1*3 
(OR=0.51)	 and	 the	 G/A	 variant	 in	 the	 promoter	 of	 SULT1E1 
(OR=1.45)	[54].
Esinler	et	al.	observed	that	patients	with	Ile/Val	(CYP1A1*2C) 
genotype	 had	 a	 5-fold	 higher	 risk	 of	 developing	 endometrial	
hyperplasia	than	those	with	Ile/Ile.	In	patients	with	endometrial	
hyperplasia	a	higher	frequency	of	Val containing	genotype	(Ile/
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Val	and	Val/Val)	was	found.	In	the	endometrial	cancer	group	the	
CYP1A1 Ile/Val	 allele	was	 also	more	 frequent	 (OR=2.54).	The	
Authors	concluded	that	variant	alleles	of	the	CYP1A1	might	be	
associated	with	endometrial	cancer	and	endometrial	hyperplasia	
risk	[9].
In	 the	 study	 performed	 by	 Doherty	 et	 al.,	 the	 Authors	
investigated	 the	 genotype	 frequency	 of	 genes	 correlated	 with	
endometrial	cancer	(CYP1A1*2A, CYP1A1*2C, CYP1A1*4.	The	
study	 involved	371	endometrial	cancer	cases	and	420	controls.	
Carrying	at	least	one	CYP1A1 m1 or m2	polymorphism	allele	was	
associated	with	a	decreased	risk	of	endometrial	cancer	(OR	0.64	
and	0.54,	respectively)	[2].
In	 summary,	 the	 findings	 of	 studies	 presented	 at	Table	 IV	
suggest	 that	 the	 CYP1A1*2A allele	 may	 decrease	 the	 risk	 of	
endometrial	cancer;	however,	the	CYP1A1*4	allele	may	increase	
a	 relative	 risk	 of	 development	 of	 this	 cancer.	 No	 association	
of	 endometrial	 cancer	 risk	was	observed	with	 any	of	 the	other	
examined	polymorphisms.
CYP1A1 gene polymorphisms and non-urogenital cancers 
In	 molecular-epidemiological	 studies	 functional	
consequences	of	*2A	and	*2C	of	CYP1A1	have	been	discussed	
to	 be	 a	 risk	 factor	 for	 lung	 cancer	 development,	 but	 not	 for	
bladder	 cancer	 [26,	 31,	 36,	 55].	 There	 is	 also	 evidence	 that	
CYP1A1	 polymorphism	 is	 closely	 associated	with	 lung	 cancer	
occurrence	[37,56].	However,	the	role	of	CYP2D6	was	analyzed	
in	recent	studies	and	it	was	also	suggest	 that	CYP2D6 is a risk 
factor	for	lung	cancer	development,	suggestion	not	confirmed	in	
other	 investigations	 [32,	57].	CYP2D6	 polymorphism	was	also	
connected	with	 liver	and	bronchial	cancers	 [58].	 In	most	cases	
the	functional	significance	of	these	polymorphisms	has	not	been	
confirmed.	These	genetic	polymorphisms	most	likely	play	a	role	in	
susceptibility	to	diseases	related	to	exposure	to	toxic	compounds	
and	could	have	direct	influence	on	the	ovarian	and	endometrial	
tissues.	 Some	 authors	 also	 suggested	 the	 overrepresentation	 of	
one	of	CYP1A1	mutations	in	the	investigated	groups	of	patients	
with	cancer.	In	molecular-epidemiological	studies,	*2A	and	*2C 
alleles were	identified	to	place	their	carrier	at	increased	risk	for	
lung	 cancer.	 High	 benzo[a]pyrene	 diol-epoxide	 DNA-adducts	
levels	in	blood	cells	occur	in	coke	oven	workers	who	are	carriers	
of	the	*2A	allele	[39,	59].
CYP1A1 and AhR – interaction important for 
carcinogenesis
The	 activity	 of	 CYP1A1	 enzyme	 that	 generates	 a	 variety	
of	 genotoxic	 metabolites	 damaging	 DNA	 and	 potentially	
promoting	cancer	development,	may	be	also	determined	by	aryl	
hydrocarbon	 receptor	 [46,60,61].	 It	 was	 shown	 that	 long-term	
exposure	to	carcinogens	is	connected	with	an	increased	risk	for	
human	malignancies,	such	as	breast	and	prostate	cancer	[62,63].	
Hence,	 both	 CYP1A1	 enzyme	 activity	 and	 action	 of	 the	 aryl	
hydrocarbon	receptor	are	claimed	to	play	an	important	role	in	the	
carcinogenesis	induced	by	many	environmental	xenobiotics.
AhR	is	a	transcription	factor	that	regulates	the	expression	of	
genes,	such	as	CYP1A1, CYP1A2	and	CYP1B1	 involved	 in	 the	
activation	and	detoxification	of	carcinogens	[61].	AhR	belongs	to	
the	class	of	basic-helix-loop-helix	(bHLH)-Per-Arnt-Sim	(PAS)	
proteins	that	is	expressed	mainly	in	human	tissues	such	as	liver,	
placenta,	 pancreas,	 lung	 and	 heart.	AhR	 ligands	 are	PAHs,	 for	
example	 benzo[a]pyrene	 and	 7,12-dimethylbenz[a]anthracene	
(DMBA),	dioxins	(2,3,7,8-tetrachlorodibenzo-p-dioxin	–	TCDD)	
as	well	 as	polychlorinated	biphenyls,	 some	dietary	 compounds	
(indole-3-carbinol)	and	several	endogenous	compounds	[64,65].	
In	the	absence	of	a	ligand,	AhR	is	maintained	in	the	cytoplasm	
in	complex	with	chaperon	proteins,	such	as	Hsp90,	ARA	(known	
as	XAP2	or	AIP)	and	p23.	After	 ligand	binding,	AhR	detaches	
from	 the	 chaperon	 proteins	 and	 translocates	 to	 the	 nucleus,	
where	 it	dimerizes	with	 the	AhR	nuclear	 translocator	 (ARNT).	
The	AhR/ARNT	 heterodimer	 binds	 to	 the	 xenobiotic	 response	
elements	 (XRE)	 of	 CYP genes	 regulating	 its	 expression	 [66].	
Furthermore,	ligand-activated	AhR	induces	a	novel	PAS	protein	
called	AhR	repressor	that	can	inhibit	AhR	by	dimerization	with	
ARNT	and	binding	to	XRE	repressing	transcription	[65,67].	An	
addition,	endogenous	AhR	was	shown	to	be	able	to	induce	cancer	
formation	 independent	of	 the	presence	of	exogenous	 ligand	by	
its	 pro-proliferative	 and	 tumour-promoting	 properties	 [62,68].	
Moreover,	the	findings	of	studies	demonstrate	overexpression	of	
the	AhR	in	the	breast	and	prostate	cancers,	suggesting	that	this	
receptor	can	be	an	important	target	for	the	development	of	new	
drugs	in	the	treatment	of	breast	and	endometrial	cancers	[62,69].	
This	is	a	new	trend	that	completes	knowledge	about	ovarian	and	
endometrial	cancer	because	not	only	CYP1A1	polymorphism,	but	
also	action	of	aryl	hydrocarbon	receptor	on	the	CYP1A1	activity	
can	 have	 significant	 importance	 in	 determining	 cancer	 risk.	
Moreover,	it	is	suggested	that	the	interactions	between	CYP1A1 
polymorphism	and	substrates	of	this	enzyme	may	increase	a	risk	
of	tumour	development.
Conclusion
In	general,	the	CYP1A1	enzyme	that	metabolizes	numerous	
procarcinogens,	 plays	 an	 important	 role	 in	 cancer	 formation.	
Several	 studies	 reported	 that	CYP1A1	 polymorphism	 could	 be	
connected	with	risk	of	appearance	of	different	types	of	cancer,	for	
example	 endometrial	 and	ovarian	malignancies.	 It	 results	 from	
the	presence	of	polymorphic	alleles	of	CYP1A1	that	alter	activity	
of	 this	 enzyme.	 Such	 interindividual	 differences	 in	 CYP1A1	
activity	may	have	influence	on	individual	susceptibility	to	cancer	
risk.	Our	analysis	presented	in	this	work	showed	an	increased	risk	
of	ovarian	and	endometrial	cancers	among	carriers	of	CYP1A1*4 
allele	and	decreased	risk	of	endometrial	cancer	for	carriers	with	
CYP1A1*2A	 allele.	No	 association	 for	 these	 discussed	 cancers	
was	observed	in	case	of	other	examined	polymorphisms.
Further	studies	are	needed	in	order	to	determine	the	functional	
consequences	 of	 genetic	 variants	 of	 CYP1A1	 enzyme	 and	
importance	of	 its	 transcriptional	 regulation	 in	 the	development	
of	 carcinogenesis.	 Moreover,	 additional	 knowledge	 about	
genetic	 risk	 factors	 for	 cancer	 progresses	 including	 CYP1A1 
polymorphism	allows	 to	determine	 the	association	between	 the	
distribution	of	specific	CYP	variant	alleles	and	risk	of	appearance	
of	tumours	including	also	ethnic	differences.
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